Liminal BioSciences Inc (Nasdaq: LMNL), a clinical-stage biopharmaceutical company, reported on Wednesday its financial results for the year ended 31 December 2020.

The company reported revenues at USD3.3m for the year ended 31 December 2020 against USD4.9m for 2019.

The firm posted net loss from continuing operations at USD122.1m for the year ended 31 December 2020 compared to USD234.2m for 2019.

Bruce Pritchard, chief executive officer of Liminal BioSciences, stated, '2021 is positioned to be an important year for key clinical trials in our small molecule therapeutics' pipeline. We look forward to completing our phase 1 MAD study and are planning to advance our lead drug candidate, fezagepras, to enter later-stage clinical trials and believe our program prioritisation positions us to capitalise on what we hope will be a pivotal year for the company.'